These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 15129429)

  • 1. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer.
    Nakamori M; Fu X; Pettaway CA; Zhang X
    Prostate; 2004 Jun; 60(1):53-60. PubMed ID: 15129429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of two newly constructed oncolytic herpes simplex viruses against renal cell carcinoma.
    Fu X; Nakamori M; Tao L; Amato R; Zhang X
    Int J Oncol; 2007 Jun; 30(6):1561-7. PubMed ID: 17487379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
    Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X
    Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
    Li H; Dutuor A; Fu X; Zhang X
    J Gene Med; 2007 Mar; 9(3):161-9. PubMed ID: 17266169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic therapy of spontaneous prostate cancer in transgenic mice with oncolytic herpes simplex viruses.
    Varghese S; Rabkin SD; Nielsen GP; MacGarvey U; Liu R; Martuza RL
    Cancer Res; 2007 Oct; 67(19):9371-9. PubMed ID: 17909046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
    Fu X; Tao L; Zhang X
    Cancer Gene Ther; 2007 May; 14(5):480-7. PubMed ID: 17290283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
    Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
    Fu X; Zhang X
    Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
    Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
    Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent oncolytic activity of human enteroviruses against human prostate cancer.
    Berry LJ; Au GG; Barry RD; Shafren DR
    Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intratumoral coadministration of hyaluronidase enzyme and oncolytic adenoviruses enhances virus potency in metastatic tumor models.
    Ganesh S; Gonzalez-Edick M; Gibbons D; Van Roey M; Jooss K
    Clin Cancer Res; 2008 Jun; 14(12):3933-41. PubMed ID: 18559615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disabled infectious single cycle herpes simplex virus (DISC-HSV) is a candidate vector system for gene delivery/expression of GM-CSF in human prostate cancer therapy.
    Parkinson RJ; Mian S; Bishop MC; Gray T; Li G; McArdle SE; Ali S; Rees RC
    Prostate; 2003 Jun; 56(1):65-73. PubMed ID: 12746848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncolytic viral gene therapy for prostate cancer using two attenuated, replication-competent, genetically engineered herpes simplex viruses.
    Cozzi PJ; Burke PB; Bhargav A; Heston WD; Huryk B; Scardino PT; Fong Y
    Prostate; 2002 Oct; 53(2):95-100. PubMed ID: 12242723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
    Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
    Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
    Ryan PC; Jakubczak JL; Stewart DA; Hawkins LK; Cheng C; Clarke LM; Ganesh S; Hay C; Huang Y; Kaloss M; Marinov A; Phipps SS; Reddy PS; Shirley PS; Skripchenko Y; Xu L; Yang J; Forry-Schaudies S; Hallenbeck PL
    Cancer Gene Ther; 2004 Aug; 11(8):555-69. PubMed ID: 15232601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung.
    Varghese S; Rabkin SD; Nielsen PG; Wang W; Martuza RL
    Clin Cancer Res; 2006 May; 12(9):2919-27. PubMed ID: 16675589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
    Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
    Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity.
    Nakamori M; Fu X; Rousseau R; Chen SY; Zhang X
    Mol Ther; 2004 May; 9(5):658-65. PubMed ID: 15120326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
    Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
    Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus.
    Fu X; Tao L; Cai R; Prigge J; Zhang X
    Mol Ther; 2006 May; 13(5):882-90. PubMed ID: 16569513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.